Table 1.
Characteristics of patients with differentiated thyroid cancer enrolled in this study
| +RAI | -RAI | P value | |
|---|---|---|---|
| No. of patients, n | 51,212 | 52,814 | |
| Patients with SMs, n(%) | 2289(4.5%) | 2339(4.4%) | 0.752 |
| Gender | < 0.001 | ||
| Female | 38,941 | 42,423 | |
| Male | 12,271 | 10,391 | |
| Median age at diagnosis of thyroid cancer (IQR), yrs | 46(36–56) | 49(38–59) | < 0.001 |
| Race | < 0.001 | ||
| White | 41,771 | 42,949 | |
| Black | 2944 | 3983 | |
| Asian and Pacific Islander | 5825 | 4816 | |
| American Indian/Alaska native | 275 | 232 | |
| Unknown | 397 | 834 | |
| Stage* | < 0.001 | ||
| Localized | 29,943(58.5%) | 43,872(83.1%) | |
| Regional | 19,304(37.7%) | 6987(13.2%) | |
| Distant | 1650(3.2%) | 635(1.2%) | |
| Unknown/unstaged | 315(0.6%) | 1320(2.5%) | |
| Median follow-up time (IQR), months | 91(57–133) | 85(52–130) | < 0.001 |
*: Localized: lesions confined to thyroid; Regional: regional by direct extension or/and regional lymph node involved; Distant: distant site(s)/lymph node involved